| ABIVAX SA EO -,01 |
| Frankreich |
| Gesundheit |
| FR0012333284 / A14UQC |
| 2X1 (Frankfurt) |
| FRA:2X1, ETR:2X1, 2X1:GR |
| - |
| https://www.abivax.com/ |
|
Abivax SA is a France-based clinical-stage biotechnology company dedicated to developing innovative therapeutics that modulate the immune response in patients with chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms, ..
>Volltext.. |
| 8204.2 Mio. EUR |
| 7705.69 Mio. EUR |
| - |
| -252.28 Mio. EUR |
| -339.78 Mio. EUR |
| -4.79 EUR |
| 32.44 Mio. EUR |
| 522.34 Mio. EUR |
| - |
| 8.42 |
| - |
| -264.35% |
| - |
| - |
| - |
| - |
| ABIVAX |
| 22.05.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|